



PERSONAL INFORMATION	
First name/Surname E-mail	Domiziana Rinaldi domiziana.rinaldi@gmail.com ; domiziana.rinaldi@uniroma1.com Italian
WORK EXPERIENCE	
- Dates (from – to) - Name and address of employer - Type of business or sector - Occupation or position held - Main activities and responsibilities	December 2024 – ongoing Azienda Ospedaliera “Sant’Andrea”, università degli studi di Roma “La Sapienza” Neurology, Neuroscience MD, Neurologist Clinical activity in an outpatient’s clinic and neurological emergency room, with a particular focus on: - Parkinson's disease and other movement disorders - Stroke, emergency unit
- Dates (from – to) - Name and address of employer - Type of business or sector - Occupation or position held - Main activities and responsibilities	February 2023 – November 2024 Ospedale “Fabrizio Spaziani”, Via Armando Fabi, Frosinone (FR) Neurology, Neuroscience MD, Neurologist Clinical activity in an outpatient’s clinic and neurological emergency room, with a particular focus on: - Parkinson's disease and other movement disorders - Stroke, neuromuscular disorders

• Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held • Main activities and responsibilities	February 2022 – December 2022 IRCCS San Raffaele, Department of Neurorehabilitation, Via della Pisana, 235, 00163 Rome, Italy Neurology, Neuroscience MD, Neurologist Clinical activity in the field of rehabilitation of neurological disorders, with a particular focus on: - Parkinson's disease and other movement disorders - Stroke - Gait disorders
• Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held • Main activities and responsibilities	January 2022 – Ongoing Sapienza, University of Rome, Doctoral School in Clinical-Experimental Neuroscience and Psychiatry. UOC Neurologia, Azienda Ospedaliera Sant'Andrea, via di Grottarossa 1035-1039, 00189, Rome, Italy PhD neuroscience MD, neurologist, PhD student Clinical activity and scientific research in the field of neurodegenerative diseases, with particular focus on: - Parkinson's disease and other movement disorders - Advanced therapies for Parkinson's disease - Mobile health Technologies

EDUCATION AND TRAINING	
• Dates (from – to) • Name and address of employer • Occupation or position held • Main activities and responsibilities	September 2023 – November 2023 "Unité des troubles du mouvement Service de Neurologie", Grenoble. Chief <i>Prof. Elena Moro</i>. Ean Clinical fellowship Winner 2023 - Collaboration for research and clinical purposes in the field of Movement Disorders Clinical activity and scientific research in the field of clinical neurology, with a special focus on clinical management and research in Movement Disorders and Deep Brain stimulation for Parkinson's disease, essential tremor, dystonia, and Tourette syndrome.

- Dates (from – to) - Name and address of employer - Occupation or position held - Main activities and responsibilities	December 2017 – December 2021 Sapienza, University of Rome, Faculty of Medicine and Surgery, Neurology residency training. UOC Neurologia, Azienda Ospedaliera Sant'Andrea, via di Grottarossa 1035-1039, 00189, Rome Italy MD, Neurology resident. Specialization in Neurology obtained with a final mark <i>70/70 cum laude</i> Clinical activity and scientific research in the field of clinical neurology, with a special focus on clinical management and research in Movement Disorders
- Dates (from – to) - Name and type of organization providing education and training - Principal subjects/occupational skills covered	February 2021 – November 2021 University of Turin, Neurology Unit, Department of Neuroscience "Rita Levi Montalcini", Città della salute e della Scienza di Torino, via Cherasco 15, 10126 Torino, Italy. Collaboration for research and clinical purposes in the field of Movement Disorders, in particular on Deep Brain Stimulation for Parkinson's disease, Essential tremor and Dystonia
- Dates - Title of qualification awarded	March 2017 License to practice medicine and inscription in the professional register.
- Dates (from – to) - Name and type of organization providing education and training - Title of qualification awarded	2010-2016 Sapienza, University of Rome, School of Medicine and Surgery Doctor in Medicine and Surgery obtained with a final mark <i>110/110 cum laude</i> Degree thesis entitled " Effect of MAO inhibition on cognitive symptoms of wearing-off in patients with Parkinson's Disease in Levodopa therapy"

PARTICIPATION IN CLINICAL TRIALS	
- Dates (from – to) - Clinical trial name - Research field - Role	2020 – 2023 Success Parkinson's disease Investigator
- Dates (from – to) - Clinical trial name - Research field - Role	2019 – 2023 IPX203-B16-03 Parkinson's disease Investigator
- Dates (from – to) - Clinical trial name - Research field - Role	2019 – 2022 IPX203-B16-02 Parkinson's Disease Investigator

• Dates (from – to) • Clinical trial name • Research field • Role	2019 – 2021 SYNAPSES Parkinson's Disease Investigator
• Dates (from – to) • Clinical trial name • Research field • Role	2016 – 2021 P14-494 DUOdopa Parkinson's Disease Investigator

PERSONAL SKILLS AND COMPETENCES

• Mother tongue	Italian
• Other language • Understanding • Listening • Reading • Speaking • Spoken interaction • Spoken production • Writing	English Fluent Fluent Fluent Fluent Fluent Fluent

OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS

2017 - Ongoing Member, Società Italiana di Neurologia (SIN)
2018 - Ongoing Member, Accademia per lo Studio della Malattia di Parkinson e i Disordini del Movimento (LIMPE)
2021 - Ongoing Member, European Academy of Neurology (EAN)
2022 - Ongoing Member, EAN Scientific Panel on Movement Disorder
2023 - 2024 Member, Direttivo Limpe Giovani

PRIZES AND AWARDS

2021 - “Avvio alla ricerca” Sapienza, University of Rome (euro 3,000)
2022 - European Academy of Neurology (EAN) - Bursary Grant
2022 - Movement Disorders Society (MDS) International Congress - Travel Grant
2022 - Congresso Nazionale Società italiana di Neurologia (SIN) - Travel Grant
2022 - “Progetto Giovani e Ricerca” Fondazione SCUDERI - Accademia LIMPE-DISMOV (euro 1,000)
2023 - European Academy of Neurology (EAN) - Bursary Grant
2023 - Winner Clinical Fellowship EAN – Movement disorder Unit, CHU Grenoble, Chief Prof. Elena Moro
2024 - European Academy of Neurology (EAN) - Bursary Grant

LIST OF SCIENTIFIC PUBLICATION IN INTERNATIONAL PEER-REVIEWED JOURNALS

1. Di Menna L, Alborghetti M, De Bartolo MI, Borro M, Gentile G, Zinni M, Bologna M, Cutrona C, D'Errico G, Imbriglio T, Bucci D, Merlo S, Ginerete RP, Orlando R, Carrillo F, Fortunato G, Cannella M, Sortino MA, Pansiot J, Baud O, Nicoletti F, Bruno V, Simmaco M, Pontieri FE, Bianchini E, **Rinaldi D**, de Curtis A, De Gaetano G, Iacoviello L, Esposito T, Berardelli A, Battaglia G. Preclinical and clinical study on type 3 metabotropic glutamate receptors in Parkinson's disease. NPJ Parkinsons Dis. 2025 Jan 4;11(1):9. doi: 10.1038/s41531-024-00860-6. PMID: 39755677; PMCID: PMC11700162.
2. Balestrino R, **Rinaldi D**, Galli S, Romagnolo A, Erro R, Ledda C, Donzuso G, Picillo M, Terravecchia C, Agosta F, Barone P, Lopiano L, Nicoletti A, Filippi M, Martinez-Martin P, Artusi CA. Expanded and independent validation of the NoMoFA scale for Parkinson's disease: the Italian version. J Neurol. 2024 Dec 28;272(1):89. doi: 10.1007/s00415-024-12863-7. PMID: 39733007.
3. Galli S, De Carolis L, Bianchini E, Alborghetti M, Calì B, Pacilio P, Fanciulli A, Pontieri FE, **Rinaldi D**. Effects of levodopa/carbidopa intestinal gel infusion on autonomic symptoms in advanced Parkinson's

disease: a systematic review. Clin Auton Res. 2024 Dec 4. doi: 10.1007/s10286-024-01090-9. Epub ahead of print. PMID: 39633032.

4. Fabbri M, Campisi C, Ledda C, **Rinaldi D**, Tsukita K, Romagnolo A, Imbalzano G, Zibetti M, Rizzone MG, Pontieri FE, Lopiano L, Artusi CA. Incidence and predictors of postural abnormalities in Parkinson's disease: a PPMI cohort study. J Neurol. 2024 May 25. doi: 10.1007/s00415-024-12457-3. Epub ahead of print. PMID: 38796527.
5. Zampogna A, Borzì L, **Rinaldi D**, Artusi CA, Imbalzano G, Patera M, Lopiano L, Pontieri F, Olmo G, Suppa A. Unveiling the Unpredictable in Parkinson's Disease: Sensor-Based Monitoring of Dyskinesias and Freezing of Gait in Daily Life. Bioengineering (Basel). 2024 Apr 29;11(5):440. doi: 10.3390/bioengineering11050440. PMID: 38790307.
6. **Rinaldi D**, Tangari MM, Ledda C, Dematteis F, Rizzone MG, Lopiano L, Artusi CA. CACNA1A variant associated with generalized dystonia. Neurol Sci. 2024 May 14. doi: 10.1007/s10072-024-07592-8. Epub ahead of print. PMID: 38743163.
7. Bianchini E, **Rinaldi D**, Alborghetti M, Simonelli M, D'Audino F, Onelli C, Pegolo E, Pontieri FE. The Story behind the Mask: A Narrative Review on Hypomimia in Parkinson's Disease. Brain Sci. 2024 Jan 22;14(1):109. doi: 10.3390/brainsci14010109. PMID: 38275529; PMCID: PMC10814039.
8. Artusi CA, Ledda C, **Rinaldi D**, Montanaro E, Romagnolo A, Imbalzano G, Rizzone MG, Zibetti M, Lopiano L, Bozzali M. Axial symptoms as main predictors of short-term subthalamic stimulation outcome in Parkinson's disease. J Neurol Sci. 2023 Sep 26;453:120818. doi: 10.1016/j.jns.2023.120818. Epub ahead of print. PMID: 37774562.
9. Alborghetti M, Bianchini E, De Carolis L, Galli S, Pontieri FE, **Rinaldi D**. Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings. Neural Regen Res. 2024 Jan;19(1):16-21. doi: 10.4103/1673-5374.375299. PMID: 37488838.
10. **Rinaldi D**, Galli S, Fanciulli A, Pontieri FE. Levodopa/carbidopa intestinal gel via percutaneous endoscopic transgastric jejunostomy in advanced Parkinson's disease: hitting two birds with one stone? Parkinsonism Relat Disord. 2023 Apr 10:105394. doi: 10.1016/j.parkreldis.2023.105394. Epub ahead of print. PMID: 37076400.
11. **Rinaldi D**, Imbalzano G, Galli S, Bianchini E, Ledda C, De Carolis L, Zibetti M, Lopiano L, Pontieri FE, Artusi CA. The impact of dysphagia in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel. Parkinsonism Relat Disord. 2023 Apr;109:105368. doi: 10.1016/j.parkreldis.2023.105368. Epub 2023 Mar 15. PMID: 36933499.
12. De Carolis L, Galli S, Bianchini E, **Rinaldi D**, Raju M, Calìò B, Alborghetti M, Pontieri FE. Age at Onset Influences Progression of Motor and Non-Motor Symptoms during the Early Stage of Parkinson's Disease: A Monocentric Retrospective Study. Brain Sci. 2023 Jan 17;13(2):157. doi: 10.3390/brainsci13020157. PMID: 36831700; PMCID: PMC9954489.
13. Bianchini E, Calìò B, Alborghetti M, **Rinaldi D**, Hansen C, Vuillerme N, Maetzler W, Pontieri FE. Step-Counting Accuracy of a Commercial Smartwatch in Mild-to-Moderate PD Patients and Effect of Spatiotemporal Gait Parameters, Laterality of Symptoms, Pharmacological State, and Clinical Variables. Sensors (Basel). 2022 Dec 25;23(1):214. doi: 10.3390/s23010214. PMID: 36616812; PMCID: PMC9823757.
14. Imbalzano G[#], **Rinaldi D**[#], Calandra-Buonaura G, Contin M, Amato F, Giannini G, Sambati L, Ledda C, Romagnolo A, Olmo G, Cortelli P, Zibetti M, Lopiano L, Artusi CA. How resistant are levodopa-resistant axial symptoms? Response of freezing, posture and voice to increasing levodopa intestinal infusion rates in Parkinson's disease Eur J N 2022. doi: 10.1111/ene.15558. Epub ahead of print. PMID: 36093563.
[#]equally contributed to the work

15. **Rinaldi D**, Alborghetti M, Bianchini E, Sforza M, Galli S, Pontieri FE. Monoamine-Oxidase type B- Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action. *Curr Neuroparmacol*. 2022 Sep 5. doi: 10.2174/1570159X20666220905102144. Epub ahead of print. PMID: 36065929.
16. Artusi CA, **Rinaldi D**, Balestrino R, Lopiano L. Deep brain stimulation for atypical parkinsonism: A systematic review on efficacy and safety. *Parkinsonism Relat Disord*. 2022 Mar;96:109-118. doi: 10.1016/j.parkreldis.2022.03.002. Epub 2022 Mar 9. PMID: 35288028.
17. Ledda C, Artusi CA, Tribolo A, **Rinaldi D**, Imbalzano G, Lopiano L, Zibetti M. Time to onset and duration of botulinum toxin efficacy in movement disorders. *J Neurol*. 2022 Feb 3. doi: 10.1007/s00415-022-10995-2. Epub ahead of print. PMID: 35113259.
18. Bianchini E, Onelli C, Morabito C, Alborghetti M, **Rinaldi D**, Anibaldi P, Marcolongo A, Salvetti M, Pontieri FE. Feasibility, Safety, and Effectiveness of Telerehabilitation in Mild-to-Moderate Parkinson's Disease. *Front Neurol*. 2022 Jun 16;13:909197. doi: 10.3389/fneur.2022.909197. PMID: 35785358; PMCID: PMC9245570.
19. **Rinaldi D**, De Carolis L, Ceriello F, Bianchini E, Pontieri FE. Levodopa/carbidopa intestinal gel for pain related to levodopa-induced motor complications in Parkinson's disease. *Neurol Sci*. 2022 Jul;43(7):4571-4572. doi: 10.1007/s10072-022-06043-6. Epub 2022 Apr 11. PMID: 35411502.
20. Andreozzi V, Princi G, Labianca L, **Rinaldi D**, Ferretti A. Magnetically Controlled Growing Rods for Early Scoliosis Treatment in Coffin-Siris Syndrome: Case Report and Literature Review. *Iowa Orthop J*. 2021;41(1):55-59. PMID: 34552404; PMCID: PMC8259188.
21. Bianchini E, Sforza M, **Rinaldi D**, Alborghetti M, De Carolis L, Della Gatta F, Pontieri FE. Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study. *Neurol Res*. 2021 Nov;43(11):950-954. doi: 10.1080/01616412.2021.1942408. Epub 2021 Jun 18. PMID: 34142645.
22. **Rinaldi D**, Sforza M, Assogna F, Savini C, Salvetti M, Caltagirone C, Spalletta G, Pontieri FE. Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study. *J Neural Transm (Vienna)*. 2021 Feb;128(2):273-277. doi: 10.1007/s00702-020-02259-y. Epub 2020 Oct 17. PMID: 33068177.
23. **Rinaldi D**, Bianchini E, Sforza M, Alborghetti M, Galli S, Salvetti M, Giovannelli M, Pontieri FE. The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study. *Aging Clin Exp Res*. 2021 Jun;33(6):1689-1692. doi: 10.1007/s40520-020-01648-3. Epub 2020 Jul 17. PMID: 32681474.
24. Sforza M, Assogna F, **Rinaldi D**, Sette G, Tagliente S, Pontieri FE. Orthostatic hypotension acutely impairs executive functions in Parkinson's disease. *Neurol Sci*. 2018 Aug;39(8):1459-1462. doi: 10.1007/s10072-018-3394-2. Epub 2018 Apr 7. PMID: 29627942.
25. **Rinaldi D**, Assogna F, Sforza M, Tagliente S, Pontieri FE. Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study. *Neurol Sci*. 2018 Jan;39(1):141-143. doi: 10.1007/s10072-017-3123-2. Epub 2017 Sep 27. PMID: 28956175.

Poster and Oral Presentation in National and International Congress	
2024 – 10th EAN Congress	A systematic review of the effects of LCIG infusion on autonomic symptoms in advanced Parkinson's disease
2023 – 9th EAN Congress	ePresentation entitled "Dysphagia and mortality in levodopa/carbidopa intestinal gel: a retrospective analysis."
2022 – MDS international Congress	Effect of levodopa-carbidopa intestinal gel on lower urinary tract symptoms in Parkinson's disease: a Urodynamic study
2022 – 8th EAN Congress	A systematic Review on Deep Brain Stimulation for Atypical Parkinsonism" A urodynamic study on the effects of levodopa-carbidopa intestinal gel on urinary symptoms in Parkinson's disease
2021 - 7° Congresso nazionale "Accademia LIMPE-DISMOV	Levodopa-carbidopa intestinal gel for managing pain related to levodopa-induced dystonia in advanced Parkinson's disease
2021- WCN - World Congress of Neurology (Virtual)	Dysautonomia in idiopathic Parkinson's Disease: relationships with distribution of motor symptoms at onset"
2021 - 51° Congresso Società Italiana di Neurologia	Intravenous immunoglobulins (IVIGs) as first line therapy for immune-mediated necrotizing myopathy (IMNM): one year follow-up in an anti-HMGCR patient
2021-MDS International Congress (Virtual)	A Pilot study of the efficacy, safety and tolerability of safinamide in elderly subjects with Parkinson's Disease
2020 - 6° Congresso nazionale Accademia LIMPE-DISMOV	A Pilot study of the efficacy, safety and tolerability of safinamide in elderly subjects with Parkinson's disease
2019 - 5° Congresso nazionale Accademia LIMPE-DISMOV	Safety and tolerability of Safinamide in elderly Parkinson's Disease patients
2018 - 4° Congresso nazionale Accademia LIMPE-DISMOV	Effect of Safinamide on dysexecutive symptoms during wearing-off in Parkinson's Disease

--	--

Autorizzo il trattamento dei miei dati personali ai sensi della normativa vigente in materia di protezione dei dati personali e, in particolare, del Codice Europeo per la protezione dei dati personali 2016/679, del Decreto Legislativo n. 196 del 30/06/2003 e successive modifiche ed integrazioni.